Trial Profile
Prospective, randomised (using minimisation), double-blind, placebo controlled study to evaluate the safety and efficacy of human normal immunoglobulin as a prophylactic agent against infections in patients with high grade gliomas.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2011
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Bacterial infections
- Focus Therapeutic Use
- 26 Aug 2011 New trial record